These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 17162013

  • 1. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
    Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, Catalona WJ.
    J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
    [Abstract] [Full Text] [Related]

  • 2. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Moul JW, Freedland SJ.
    J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
    [Abstract] [Full Text] [Related]

  • 3. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ.
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [Abstract] [Full Text] [Related]

  • 4. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC.
    Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
    [Abstract] [Full Text] [Related]

  • 5. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H.
    J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
    [Abstract] [Full Text] [Related]

  • 6. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
    Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, Isaacs WB, Partin AW.
    J Urol; 2005 Sep; 174(3):919-22. PubMed ID: 16093988
    [Abstract] [Full Text] [Related]

  • 7. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ, Sun L, Kane CJ, Presti JC, Terris MK, Amling CL, Moul JW, Aronson WJ.
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [Abstract] [Full Text] [Related]

  • 8. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
    Loeb S, Sutherland DE, D'Amico AV, Roehl KA, Catalona WJ.
    Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
    [Abstract] [Full Text] [Related]

  • 9. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A, Rais-Bahrami S, Peck HJ, Walsh PC, Epstein JI, Trock BJ, Gonzalgo ML.
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [Abstract] [Full Text] [Related]

  • 10. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN, Koch MO.
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [Abstract] [Full Text] [Related]

  • 11. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
    Freedland SJ, Kane CJ, Presti JC, Terris MK, Amling CL, Dorey F, Aronson WJ.
    J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
    [Abstract] [Full Text] [Related]

  • 12. Pathological features after radical prostatectomy in potential candidates for active monitoring.
    Griffin CR, Yu X, Loeb S, Desireddi VN, Han M, Graif T, Catalona WJ.
    J Urol; 2007 Sep; 178(3 Pt 1):860-3; discussion 863. PubMed ID: 17631347
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
    Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, Catalona WJ.
    J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
    [Abstract] [Full Text] [Related]

  • 15. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML.
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Laparoscopic extraperitoneal radical prostatectomy in complex surgical cases.
    Rodriguez AR, Kapoor R, Pow-Sang JM.
    J Urol; 2007 May; 177(5):1765-70. PubMed ID: 17437812
    [Abstract] [Full Text] [Related]

  • 18. Obesity and capsular incision at the time of open retropubic radical prostatectomy.
    Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, Epstein JI, Partin AW.
    J Urol; 2005 Nov; 174(5):1798-801; discussion 1801. PubMed ID: 16217290
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ.
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.